Literature DB >> 19289176

Overexpression of E2F-1 inhibits progression of gastric cancer in vitro.

Yubo Xie1, Changqing Wang, Lei Li, Yulin Ma, Yongshuo Yin, Qiang Xiao.   

Abstract

E2F-1 plays a critical role in cell cycle regulation and other biological processes in cells. E2F-1 mediates apoptosis and suppresses tumorigenesis in many tissue types, but there are few data available on E2F-1 expression and its relationship to tumor kinetics in gastric cancer. To gain better insight into the involvement of E2F-1 in the biological characteristics of gastric tumors, we investigated the effect of E2F-1 overexpression on the progression of gastric carcinoma cells. A gastric cancer cell line stably overexpressing E2F-1 (MGC-803/E2F-1) was established. The influence of E2F-1 overexpression on in vitro cell growth was assessed by measuring cell survival, colony formation, and cell cycle progression. The results clearly show that overexpression of E2F-1 significantly inhibits cell growth and proliferation, blocking entry into the S-phase of the cell cycle. MGC-803/E2F-1 cells also had a higher apoptotic rate than control cells. In addition, E2F-1 reduced the motility and invasion of gastric cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289176     DOI: 10.1016/j.cellbi.2009.02.015

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  11 in total

1.  siRNA targeting of Cdx2 inhibits growth of human gastric cancer MGC-803 cells.

Authors:  Xiao-Tong Wang; Yu-Bo Xie; Qiang Xiao
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

2.  Lentivirus-mediated RNA interference targeting E2F-1 inhibits human gastric cancer MGC-803 cell growth in vivo.

Authors:  Xiao Tong Wang; Yu Bo Xie; Qiang Xiao
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

Review 3.  E2F transcription factors and digestive system malignancies: how much do we know?

Authors:  Athanasios Xanthoulis; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

4.  Transcriptome analysis of hepatocytes after partial hepatectomy in rats.

Authors:  Cunshuan Xu; Xiaoguang Chen; Cuifang Chang; Gaiping Wang; Wenbo Wang; Lianxing Zhang; Qiushi Zhu; Lei Wang; Fuchun Zhang
Journal:  Dev Genes Evol       Date:  2010-11-17       Impact factor: 0.900

5.  E2F-1 overexpression inhibits human gastric cancer MGC-803 cell growth in vivo.

Authors:  Wei-Yuan Wei; Lin-Hai Yan; Xiao-Tong Wang; Lei Li; Wen-Long Cao; Xiao-Shi Zhang; Ze-Xu Zhan; Han Yu; Yu-Bo Xie; Qiang Xiao
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

6.  E2F-1 targets miR-519d to regulate the expression of the ras homolog gene family member C.

Authors:  Xiu-Bo Sang; Zhi-Hong Zong; Li-Li Wang; Dan-Dan Wu; Shuo Chen; Bo-Liang Liu; Yang Zhao
Journal:  Oncotarget       Date:  2017-02-28

7.  E2F1 induces LSINCT5 transcriptional activity and promotes gastric cancer progression by affecting the epithelial-mesenchymal transition.

Authors:  Peng Qi; Wan-Run Lin; Meng Zhang; Dan Huang; Shu-Juan Ni; Xiao-Li Zhu; Qian-Ming Bai; Wei-Qi Sheng; Xiang Du; Xiao-Yan Zhou
Journal:  Cancer Manag Res       Date:  2018-08-10       Impact factor: 3.989

Review 8.  Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?

Authors:  P Meng; R Ghosh
Journal:  Cell Death Dis       Date:  2014-08-07       Impact factor: 8.469

9.  E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1/CDKN2B signaling axis.

Authors:  Tong-Peng Xu; Yan-Fen Wang; Wei-Liang Xiong; Pei Ma; Wen-Yu Wang; Wen-Ming Chen; Ming-De Huang; Rui Xia; Rong Wang; Er-Bao Zhang; Yan-Wen Liu; Wei De; Yong-Qian Shu
Journal:  Cell Death Dis       Date:  2017-06-01       Impact factor: 8.469

10.  Novel Potential Therapeutic Target for E2F1 and Prognostic Factors of E2F1/2/3/5/7/8 in Human Gastric Cancer.

Authors:  Xuhong Liu; Chunhong Hu
Journal:  Mol Ther Methods Clin Dev       Date:  2020-07-31       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.